REVB (Revelation Biosciences) ROE % Adjusted to Book Value: -306.03% (As of Mar. 2026)


REVB Revelation Biosciences Inc REVB
28 GF Score
Price $0.98
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences ROE % Adjusted to Book Value?

Revelation Biosciences REVB +3.16% 28 ROE % Adjusted to Book Value is -306.03% as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Revelation Biosciences's ROE % for the quarter that ended in Mar. 2026 was -110.17%. Revelation Biosciences's PB Ratio for the quarter that ended in Mar. 2026 was 0.36. Revelation Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -306.03%.

Revelation Biosciences ROE % Adjusted to Book Value Related Terms

Revelation Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences ROE % Adjusted to Book Value Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 -7.26 -319.11 -230.51

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -245.69 -323.91 -223.67 -177.42 -306.03

REVB vs ITRMF, ENSC, PPCB: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Revelation Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's ROE % Adjusted to Book Value falls into.


REVB
28GF Score
Revelation Biosciences Inc REVB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences ROE % Adjusted to Book Value Calculation

Revelation Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-131.39% / 0.57
=-230.51%

Revelation Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-110.17% / 0.36
=-306.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -306.03% mean?
Revelation Biosciences (REVB) has a ROE % Adjusted to Book Value of -306.03% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Revelation Biosciences and its competitors.
Is Revelation Biosciences' ROE % Adjusted to Book Value too high?
Revelation Biosciences' current ROE % Adjusted to Book Value is -306.03%. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' ROE % Adjusted to Book Value compare to ITRMF and ENSC?
Revelation Biosciences' ROE % Adjusted to Book Value of -306.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current ROE % Adjusted to Book Value is -306.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current ROE % Adjusted to Book Value of -306.03%. The current ROE % Adjusted to Book Value is -306.03%. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current ROE % Adjusted to Book Value is -306.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price